| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 22.58 | -0.50 (-2.17%) | 7.56 - 24.04 | 568.8 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 23.03 |
|---|---|
| Previous Close | 23.08 |
| Day's Range | 22.45 - 23.03 |
| Market Cap | 2.6B |
| Avg Volume (10 Day) | 866.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.42 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics
PR Newswire - Tuesday 06/18/2013 8:00 AM ET
Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
PR Newswire - Tuesday 06/18/2013 7:00 AM ET
Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
PR Newswire - Monday 06/10/2013 7:00 AM ET
Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
PR Newswire - Thursday 06/06/2013 7:00 AM ET
Isis Pharmaceuticals to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
PR Newswire - Wednesday 06/05/2013 7:00 AM ET
Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
PR Newswire - Monday 06/03/2013 2:00 PM ET
Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer
PR Newswire - Monday 06/03/2013 7:00 AM ET
Isis Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Friday 05/31/2013 4:30 PM ET
| ISIS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 20.76% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 1.13 | |
| LT Debt/Equity | 1.11 | |
| Earnings Yield | -- | |
| Price/Sales | 21.42 |
| Company | Last | Change |
|---|---|---|
| Taro Pharmaceutical Industries Ltd | 57.57 | -0.02% |
| United Therapeutics Corp | 64.99 | -1.04% |
| Cubist Pharmaceuticals Inc | 49.97 | -2.27% |
| The Medicines Co | 33.52 | +3.04% |
| Amarin Corporation PLC | 6.47 | -1.97% |
Data is delayed by at least 15 min.